FDA approves ibrutinib to treat mantle cell lymphoma

Farydak (panobinostat) now FDA-approved for multiple myeloma
Farydak (panobinostat) now FDA-approved for multiple myeloma

(HealthDay News) -- Imbruvica (ibrutinib) has been approved by the U.S. Food and Drug Administration to treat mantle cell lymphoma (MCL).

MCL represents about 6 percent of non-Hodgkin lymphoma cases, the agency said Wednesday in a news release. By the time it's usually diagnosed, it has spread to other areas such as the lymph nodes or bone marrow.

Imbruvica, designed to inhibit an enzyme that cancer cells need to spread, was granted the FDA's rare "breakthrough therapy" status as a drug that promises to offer a "substantial improvement over available therapies for patients with serious or life-threatening diseases," the agency said.

Imbruvica was evaluated in a study of 111 participants. Of those who took the drug daily, 66 percent had their cancer shrink or disappear, the FDA said. The most common side effects included thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, edema, and upper respiratory infection.

Imbruvica is co-marketed by Sunnyvale, Calif.-based Pharmacyclics, and Raritan, N.J.-based Janssen Biotech.

More Information

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs